Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jon Jacobsen

Showing results (11-20 of 20) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 20 results.
Bioorganic & Medicinal Chemistry Letters|August 9, 2023
Positive allosteric modulators of the α7 nicotinic acetylcholine receptor: SAR investigation around PNU-120596Brad A Acker, Valentina O Badescu, Mitchell B Berkenpas, et al.
Bioorganic & Medicinal Chemistry Letters|May 21, 2008
Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activityBrad A Acker, E Jon Jacobsen, Bruce N Rogers, et al.
Bioorganic & Medicinal Chemistry Letters|July 28, 2009
Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-oneRobert O Hughes, John K Walker, D Joseph Rogier, et al.
Bioorganic & Medicinal Chemistry Letters|June 23, 2009
Investigation of aminopyridiopyrazinones as PDE5 inhibitors: Evaluation of modifications to the central ring systemRobert O Hughes, John K Walker, Jerry W Cubbage, et al.
Journal of Medicinal Chemistry|March 4, 2010
Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5)Robert O Hughes, D Joseph Rogier, E Jon Jacobsen, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 2025
Characterization of the dual ITK/JAK3 small molecule covalent inhibitor ATI-2138Aparna Kaul, Heidi Hope, Canxin Xu, et al.
Bioorganic & Medicinal Chemistry Letters|June 23, 2009
Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitorsDafydd R Owen, John K Walker, E Jon Jacobsen, et al.
BMJ (Clinical Research Ed.)|June 24, 2006
Effect of perioperative beta blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trialAnne Benedicte Juul, Jørn Wetterslev, Christian Gluud, et al.
Journal of Medicinal Chemistry|July 11, 2006
Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationshipDonn G Wishka, Daniel P Walker, Karen M Yates, et al.
Bioorganic & Medicinal Chemistry|October 3, 2006
Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as alpha7 nicotinic acetylcholine receptor agonistsDaniel P Walker, Donn G Wishka, David W Piotrowski, et al.
Pageof 2

Showing results (11-20 of 20) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 20 results.
Bioorganic & Medicinal Chemistry Letters|August 9, 2023
Positive allosteric modulators of the α7 nicotinic acetylcholine receptor: SAR investigation around PNU-120596Brad A Acker, Valentina O Badescu, Mitchell B Berkenpas, et al.
Bioorganic & Medicinal Chemistry Letters|May 21, 2008
Discovery of N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide as an agonist of the alpha7 nicotinic acetylcholine receptor: in vitro and in vivo activityBrad A Acker, E Jon Jacobsen, Bruce N Rogers, et al.
Bioorganic & Medicinal Chemistry Letters|July 28, 2009
Optimization of the aminopyridopyrazinones class of PDE5 inhibitors: discovery of 3-[(trans-4-hydroxycyclohexyl)amino]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-oneRobert O Hughes, John K Walker, D Joseph Rogier, et al.
Bioorganic & Medicinal Chemistry Letters|June 23, 2009
Investigation of aminopyridiopyrazinones as PDE5 inhibitors: Evaluation of modifications to the central ring systemRobert O Hughes, John K Walker, Jerry W Cubbage, et al.
Journal of Medicinal Chemistry|March 4, 2010
Design, synthesis, and biological evaluation of 3-[4-(2-hydroxyethyl)piperazin-1-yl]-7-(6-methoxypyridin-3-yl)-1-(2-propoxyethyl)pyrido[3,4-b]pyrazin-2(1H)-one, a potent, orally active, brain penetrant inhibitor of phosphodiesterase 5 (PDE5)Robert O Hughes, D Joseph Rogier, E Jon Jacobsen, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 1, 2025
Characterization of the dual ITK/JAK3 small molecule covalent inhibitor ATI-2138Aparna Kaul, Heidi Hope, Canxin Xu, et al.
Bioorganic & Medicinal Chemistry Letters|June 23, 2009
Identification, synthesis and SAR of amino substituted pyrido[3,2b]pyrazinones as potent and selective PDE5 inhibitorsDafydd R Owen, John K Walker, E Jon Jacobsen, et al.
BMJ (Clinical Research Ed.)|June 24, 2006
Effect of perioperative beta blockade in patients with diabetes undergoing major non-cardiac surgery: randomised placebo controlled, blinded multicentre trialAnne Benedicte Juul, Jørn Wetterslev, Christian Gluud, et al.
Journal of Medicinal Chemistry|July 11, 2006
Discovery of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]furo[2,3-c]pyridine-5-carboxamide, an agonist of the alpha7 nicotinic acetylcholine receptor, for the potential treatment of cognitive deficits in schizophrenia: synthesis and structure--activity relationshipDonn G Wishka, Daniel P Walker, Karen M Yates, et al.
Bioorganic & Medicinal Chemistry|October 3, 2006
Design, synthesis, structure-activity relationship, and in vivo activity of azabicyclic aryl amides as alpha7 nicotinic acetylcholine receptor agonistsDaniel P Walker, Donn G Wishka, David W Piotrowski, et al.
Pageof 2